Prospera Financial Services Inc Intercept Pharmaceuticals, Inc. Transaction History

Prospera Financial Services Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.99 - $18.71 $35,014 - $65,578	-3,505 Reduced 10.08%	31,262 $579,000
Q2 2023 Aug 08, 2023	BUY	$9.17 - $19.29 $28,289 - $59,509	3,085 Added 9.74%	34,767 $384,000
Q1 2023 May 12, 2023	SELL	$12.53 - $21.71 $1,553 - $2,692	-124 Reduced 0.39%	31,682 $425,000
Q4 2022 Feb 08, 2023	BUY	$11.61 - $16.11 $33,854 - $46,976	2,916 Added 10.09%	31,806 $393,000
Q3 2022 Oct 27, 2022	BUY	$12.21 - $19.7 $45,543 - $73,481	3,730 Added 14.83%	28,890 $403,000
Q2 2022 Aug 08, 2022	SELL	$11.23 - $19.59 $9,803 - $17,102	-873 Reduced 3.35%	25,160 $347,000
Q1 2022 May 04, 2022	BUY	$13.37 - $17.79 $74,404 - $99,001	5,565 Added 27.19%	26,033 $424,000
Q4 2021 Feb 10, 2022	BUY	$14.28 - $19.53 $7,354 - $10,057	515 Added 2.58%	20,468 $333,000
Q3 2021 Nov 12, 2021	BUY	$12.99 - $20.47 $81,408 - $128,285	6,267 Added 45.79%	19,953 $296,000
Q2 2021 Aug 12, 2021	BUY	$15.46 - $24.5 $211,585 - $335,307	13,686 New	13,686 $273,000
Q4 2020 Feb 12, 2021	SELL	$24.48 - $42.47 $16,719 - $29,007	-683 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$39.09 - $53.44 $26,698 - $36,499	683 New	683 $28,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.